Canopy Growth Corporation is on strong long term bullish price action both on 1W (RSI = 58.856, MACD = 4.873, Highs/Lows = 2.6189) and 1M (RSI = 66.122, MACD = 12.099, Highs/Lows = 7.3414). Since mid 2017 in particular, it has been trading on Higher Lows reaching +1000% in growth. Using the Pitchfork to identify the pressure zone, we estimate that the asset is...
Breakout about the 100 day VWMA and CCI is crawling out of the hole, another rush upwards is in the works. To what point is anyone's guess. Personally not going to buy in unless it has a nice pullback toward the 2.00 level.
Best to play this like anything else - with patience and discipline.
Today we gonna look at the pharmaceutical company, as a potential new giant trend on the stock market. NASDAQ:BMRN laying on the strong support line near $87.87 and can move up suddenly. My recommendation:
1. Buy now around 87.87
2. Take profit: 109.45
3. SL: 78.68
Risk/Reward - 2.39, potential profit - 24,6%
Aspen is a global supplier and manufacturer of branded and generic pharmaceutical products as well as infant nutritionals and consumer healthcare products in selected territories.
ASPEN has been under the microscope over the past few years with various negative rumors and investigations driving the share price lower and lower. I believe that we haven't quite seen...
NVS Novartis owns or makes a slew of pharmacopial needs for a variety of medical needs.
Little dip during recent pullback.
Watching Friday ads, all brand names no companies. All Novartis or made for another company by Novartis.
There are several aspects to this chart- the wave analysis is certainly up for debate, but what remains is improving fundamentals.
On this chart we have a corrective sequence ABC starting in 2014 and concluding in early 2017. On this chart, we can see the 30 day MA volume skyrockets in the beginning of 2017. This corresponds to the timing of the Obama...
following the stock as 5 directors purchased hundreds of thousands of stock for the price of 24 cents on sept 21st just as it started to move sideways and broke out of the resistance. It broke out of its strong downward channel, so I'll be monitoring it to see any significant runs. This is also the beginning of a golden cross if im not mistaken.
Medical stock that's too thinly traded got mixed review on clinical trial results on Tivozanib, which showed efficacy, just not to level expected and testing new low for 2018 at 2.03 and below full fibonacci retracement of 2.10 as prior low. NASDAQ:AVEO
This is the weekly chart on Loxo Oncology. This biotech focuses on cancer treatments by targeting genetic mutations that create protein chimers that lead to unregulated cellular proliferation. In English, and very simply, imagine a copy machine. When you press 'Copy' you should get one duplicate of the item you want copied. Cells have similar systems where a...